日本糖尿病市場報告：2026-2034年

2025年，日本糖尿病市場規模達58億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到76億美元，2026年至2034年的複合年成長率為2.95%。推動該市場成長要素包括老年人口增加、糖尿病盛行率上升、政府支持措施帶來的醫療保健支出增加以及治療方法的進步。

日本糖尿病市場分析：

• 市場主要促進因素：生活方式的改變和人口老化導致日本糖尿病盛行率不斷上升，這是成長要素。此外，近期調查顯示，糖尿病患者人數持續成長，進一步刺激了日本糖尿病市場的需求。政府也已撥款並實施多項衛生措施，以加強糖尿病的治療和管理。這些措施包括糖尿病治療補助和旨在促進市場擴張的公共衛生措施。
• 市場主要趨勢：胰島素幫浦和持續血糖監測儀（CGM）等先進的糖尿病照護技術正日益普及。此外，受遺傳因素研究進展以及患者對更有效率、更專業的糖尿病管理方案的個人化需求的推動，個人化治療方案和定製藥物的使用也成為一種趨勢。
• 競爭格局：日本糖尿病市場由大型國際製藥公司和醫療設備製造商主導。這些公司憑藉豐富的產品線和最尖端科技保持競爭力。此外，日本公司也提供創新產品和客製化解決方案，以滿足日本患者的需求。
• 挑戰與機會：市場挑戰包括對新型糖尿病治療方法的嚴格監管和漫長的核准流程。另一方面，人口老化為開發針對該族群的糖尿病治療和管理方案提供了巨大機會。此外，遠端醫療和行動醫療應用等數位健康技術的進步，也為更深入與患者互動和改善糖尿病管理創造了新的可能性。

日本糖尿病市場的發展趨勢：

糖尿病盛行率不斷上升

日本糖尿病市場的成長主要受糖尿病盛行率上升的驅動。根據國際糖尿病聯盟（IDF）的數據，截至2021年，日本成年人口為93,187,400，糖尿病盛行率為11.8%，即11,004,999人。因此，由於對包括先進藥物和監測設備在內的綜合糖尿病護理解決方案的需求不斷成長，市場正在擴張。此外，隨著患者人數的增加，製藥公司和醫療保健專業人員被迫研發並提供各種治療方案，以滿足患者的多樣化需求。同時，隨著糖尿病患者人數的增加，旨在改善患者治療效果和生活品質的糖尿病專科醫療保健服務也不斷擴展。因此，這一趨勢正在推動抗糖尿病藥物的銷售，並刺激創新血糖監測技術的市場發展，這些技術有望提供更精準、更便捷的監測方案，從而為日本糖尿病市場帶來光明的前景。

人口老化的過程

根據內務部的報告，截至2023年9月15日，日本65歲以上人口已達3,622.7萬人。此外，老年人口佔總人口的比例上升了0.1個百分點，達到29.1%，創歷史新高。由於老年人更容易患上第2型糖尿病，因此對專業的糖尿病管理項目和產品的需求日益成長。受人口結構變化的影響，醫療機構和臨床醫生正致力於老年糖尿病的治療，推動藥物治療、營養指導和病患教育等方面的進步，使其更符合老年人的需求。人口老化也影響現有高需求服務和產品的供應。這些服務和產品易於使用且侵入性小，非常適合老年患者，因此也導致了糖尿病治療需求的增加。

政府支持措施和醫療成本

日本政府積極加大醫療保健支出力度，包括為治療糖尿病等慢性疾病撥出大量預算，正推動日本糖尿病市場的發展。根據Frontiers統計，2020年日本國民醫療保健支出飆升至43兆日圓（約3,040億美元），幾乎是1990年的兩倍。這相當於其占國內生產總值的比重從4.6%上升至8.0%。此外，政府正致力於確保糖尿病照護資金充足，改善治療可近性，並控制治療費用。這些項目涵蓋從先進治療方法方案到一級預防的各個方面，正在夯實糖尿病護理的基礎。同時，眾多政府主導的、以篩檢和公共衛生宣傳活動為重點的舉措，旨在降低糖尿病盛行率並改善社區層面的主導，這些舉措也促進了市場成長。因此，這些全面的健康政策透過提高意識提升、促進早期發現以及將先進的糖尿病護理納入公共衛生體系，正在推動日本糖尿病市場的成長。

目錄

第1章：序言

第2章：調查方法

• 調查目的
• 相關利益者
• 數據來源
  • 主要訊息
  • 次要訊息
• 市場估值
  • 自下而上的方法
  • 自上而下的方法
• 預測方法

第3章執行摘要

第4章：引言

第5章：糖尿病概述

• 什麼是糖尿病？
• 糖尿病的診斷和治療
  • 診斷
  • 治療
• 糖尿病併發症

第6章：日本糖尿病流行病學

• 糖尿病患者人數及盛行率
• 人口和盛行率：按糖尿病類型（1 型和 2 型）分類
• 人口和盛行率：按地區分類
• 人口和盛行率：按性別分類
• 人口和盛行率：按年齡層別分類

第7章：日本糖尿病市場

• 市場概覽
• 市場表現
• 新冠疫情的影響
• 市場預測
• SWOT分析
• 價值鏈分析
• 波特五力分析
• 市場區隔：按細分市場

第8章 競爭情勢

• 市場結構
• 主要企業簡介

The Japan diabetes market size reached USD 5.8 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 7.6 Billion by 2034, exhibiting a growth rate (CAGR) of 2.95 % during 2026-2034. The market is primarily driven by the growing geriatric population, increased prevalence of diabetes, enhanced healthcare spending with supportive government initiatives, and technological advancements in treatment options.

JAPAN DIABETES MARKET ANALYSIS:

• Major Market Drivers: The rising prevalence of diabetes in Japan due to the changing lifestyles and an aging population represents a major growth-inducing factor. In addition, recent research indicates that the diabetic patient population is still growing, which is increasing the Japan diabetes market demand. Besides, the government has funded and executed several health initiatives to enhance the treatment and management of diabetes. These include diabetes treatment subsidies and public health initiatives that encourage market expansion.
• Key Market Trends: Advanced diabetes care technology like insulin pumps and continuous glucose monitors (CGMs) are becoming more popular. Moreover, the market is witnessing a trend toward individualized treatment plans and customized medicines, which is driven by greater research into genetic variables and unique patient demands to deliver more efficient and specialized diabetes management solutions.
• Competitive Landscape: The Japanese diabetes market is dominated by giant international pharmaceutical and medical device businesses, as their wide range of products and cutting-edge technology help them to stay competitive. Additionally, Japanese companies are offering innovations and customized solutions specific to the requirements of Japanese patients.
• Challenges and Opportunities: Challenges in the market include stringent regulatory regulations and protracted approval procedures for novel diabetic therapies. On the other hand, the growing geriatric population offers substantial opportunities for the development of diabetes treatment and management programs specifically designed for this demographic. Besides, the development of digital health technologies, such as telemedicine and mobile health apps, creates new possibilities for better patient engagement and diabetes management.

JAPAN DIABETES MARKET TRENDS :

Rising Diabetes Prevalence

The growth of the diabetes market in Japan is driven by the rising incidence of diabetes. According to the International Diabetes Federation (IDF) reports, with 93,187,400 individuals in the country as of 2021, the prevalence rate of diabetes is 11.8% or 11,004,999 cases among adults. As a result, the market is expanding due to the increasing need for complete diabetes care solutions, which include cutting-edge drugs and monitoring equipment. Moreover, pharmaceutical businesses and healthcare professionals are compelled by the increasing number of patients to create and offer a wide array of treatment alternatives that address the diverse demands of their patients. In addition, the rise in diabetes cases has increased diabetes-specific healthcare services that attempt to enhance patient outcomes and quality of life. Hence, this trend has propelled the sales of anti-diabetic medications and boosted the market for innovative glucose monitoring technologies that promise more accurate and user-friendly options, thus creating a positive Japan diabetes market outlook.

Growing Geriatric Population

As reported by the Ministry of Internal Affairs and Communications, Japan's elderly population, those aged 65 and above, reached 36,227 thousand as of September 15, 2023. Moreover, the proportion of seniors in the overall population increased by 0.1% points to 29.1%, the highest percentage ever recorded. Additionally, the elderly are more susceptible to type 2 diabetes , which escalates the need for specialized diabetes management programs and products. This change in the population motivates healthcare organizations and clinicians to concentrate on the treatment of geriatric diabetes, resulting in advancements in medication therapy, nutritional guidance, and patient education customized to the needs of the geriatric population. Besides, the aging population influences several services and products that are in demand, offer simple use and low invasiveness, which are ideal for senior patients, and increase the volume of diabetic treatments that are necessary.

Supportive Government Initiatives and Healthcare Spending

The diabetes market is driven by the government of Japan's aggressive approach to healthcare spending, which includes a sizeable budget for treating chronic illnesses like diabetes. According to Frontiers, in 2020, Japan's national medical spending skyrocketed to 43 Trillion yen (304 Billion USD), nearly doubling from past figures since 1990. This indicates an increase in the nation's gross domestic output from 4.6% to 8.0%. In addition, the government ensures that enough money is spent on diabetes care, which makes treatments more accessible and reasonably priced. The foundation of diabetes care is being improved due to these programs, which cover everything from sophisticated treatment choices to primary prevention. In addition, numerous government initiatives concentrated on screenings and public health campaigns to lower the prevalence of diabetes while improving its management at the community level are influencing the market growth. Hence, these comprehensive health policies support Japan diabetes market growth by increasing awareness and early detection while integrating advanced diabetes care into the public health system.

JAPAN DIABETES MARKET SEGMENTATION:

Breakup by Segment:

• Oral Antidiabetics
• Insulin

Insulin accounts for the majority of the market share

Insulin reflects a substantial portion of the market share due to the increasing prevalence of diabetes among the aging population and the rising adoption of insulin therapies for effective glucose management. Additionally, Japan's healthcare system, renowned for its efficiency, extensively supports diabetes care, enabling widespread access to insulin treatments. Moreover, the market benefits from advancements in insulin formulations and delivery systems, which enhance patient adherence and outcomes. Besides, the Japanese government's proactive health initiatives aim to improve diabetes awareness and screening, further driving the demand for insulin. Furthermore, this segment's growth is also fueled by collaborations between domestic pharmaceutical companies and global diabetes care leaders, aiming to innovate and expand the availability of cutting-edge insulin solutions tailored to the unique needs of Japanese patients. Hence key players are introducing advanced product variants to meet these needs. For instance, in March 2023, in Tokyo Japan, and Taipei, Taiwan, Health2Sync, announced the recent update of its Health2Sync App now including insulin data from the Mallya Cap, a connected device for insulin pens created by Biocorp and marketed in Japan by Novo Nordisk. This collaboration introduces the world's first integration of this type of data and is designed to aid patients undergoing insulin treatment by tracking various health metrics, such as insulin injection records. Due to these innovations, the Japan diabetes market forecast states that insulin segment will continue to dominate the market.

COMPETITIVE LANDSCAPE:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have been provided.
• At present, key players in the market are actively enhancing growth through strategic collaborations, advanced research and development (R&D) initiatives, and educational programs to improve diabetes management. Additionally, companies like Novo Nordisk and Sanofi are investing heavily in the development of next-generation insulin therapies and glucose monitoring systems tailored to meet the specific needs of Japanese patients, thus accounting for the Japan diabetes market share. These firms collaborate closely with local healthcare providers to ensure broad distribution and integration of their products into daily medical practice. Furthermore, these market leaders support extensive patient education campaigns to increase awareness about diabetes symptoms, treatment options, and lifestyle adjustments necessary for effective disease management. These comprehensive strategies strengthen their market position and significantly contribute to improving patient outcomes in Japan. For instance, on 29 March 2023, Maryland, Astellas Pharma Inc. announced its partnership with Roche Diabetes Care Japan Co., Ltd. This partnership focuses on the development and commercialization of the globally recognized Accu-Chek Guide Me blood glucose monitoring system, noted for its high accuracy, in conjunction with BlueStar(R)*1. BlueStar, an FDA-approved digital health solution for managing diabetes, is developed by Welldoc, Inc. and is available in the U.S. and Canada. Astellas and Welldoc are collaboratively advancing BlueStar's development in Japan. Astellas plans to seek regulatory approval and reimbursement for this integrated medical product in the future.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How has the Japan diabetes market performed so far, and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan diabetes market?
• What is the breakup of the Japan diabetes market on the basis of segment?
• What are the various stages in the value chain of the Japan diabetes market?
• What are the key driving factors and challenges in the Japan diabetes market?
• What is the structure of the Japan diabetes market, and who are the key players?
• What is the degree of competition in the Japan diabetes market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Diabetes Disease Overview

• 5.1 What is Diabetes?
• 5.2 Diabetes Diagnosis and Treatment
  • 5.2.1 Diagnosis
  • 5.2.2 Treatment
• 5.3 Diabetes Complications

6 Japan Diabetes Epidemiology

• 6.1 Diabetes Population and Prevalence Rates
• 6.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2)
• 6.3 Population and Prevalence Rates by Region
• 6.4 Population and Prevalence Rates by Gender
• 6.5 Population and Prevalence Rates by Age Group

7 Japan Diabetes Market

• 7.1 Market Overview
• 7.2 Market Performance
• 7.3 Impact of COVID-19
• 7.4 Market Forecast
• 7.5 SWOT Analysis
  • 7.5.1 Overview
  • 7.5.2 Strengths
  • 7.5.3 Weaknesses
  • 7.5.4 Opportunities
  • 7.5.5 Threats
• 7.6 Value Chain Analysis
• 7.7 Porter's Five Forces Analysis
  • 7.7.1 Overview
  • 7.7.2 Bargaining Power of Buyers
  • 7.7.3 Bargaining Power of Suppliers
  • 7.7.4 Degree of Competition
  • 7.7.5 Threat of New Entrants
  • 7.7.6 Threat of Substitutes
• 7.8 Market Breakup by Segment
  • 7.8.1 Japan Oral Antidiabetics Market
    • 7.8.1.1 Historical Market Trends
    • 7.8.1.2 Market Breakup by Class
    • 7.8.1.3 Market Shares of Key Players
    • 7.8.1.4 Market Forecast
  • 7.8.2 Japan Insulin Market
    • 7.8.2.1 Historical Market Trends
    • 7.8.2.2 Market Breakup by Class
    • 7.8.2.3 Market Shares of Key Players
    • 7.8.2.4 Market Forecast

8 Competitive Landscape

• 8.1 Market Structure
• 8.2 Profiles of Key Players

List of Figures

• Figure 1: The Impact of Diabetes in the Human Body
• Figure 2: Diabetes Complications
• Figure 3: Global: Breakup of Diabetes Patients by Region, (in %) 2025 & 2034
• Figure 4: Body Mass Index and Relative risk of Type-2 Diabetes
• Figure 5: Japan: Total Number of Diabetes Patients (in 000), 2020-2025
• Figure 6: Japan: Total Number of Diabetes Patients Forecast (in 000), 2026-2034
• Figure 7: Japan (Type1 & Type2): Total Number of Diabetes Patients (in 000), 2020-2025
• Figure 8: Japan (Type1 & Type2): Total Number of Diabetes Patients Forecast (in 000), 2026-2034
• Figure 9: Japan (Urban & Rural): Total Number of Diabetes Patients (in 000), 2020-2025
• Figure 10: Japan (Urban & Rural): Total Number of Diabetes Patients Forecast (in 000), 2026-2034
• Figure 11: Japan (Male & Female): Total Number of Diabetes Patients (in 000), 2020-2025
• Figure 12: Japan (Male & Female): Total Number of Diabetes Patients Forecast (in 000), 2026-2034
• Figure 13: Japan: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in 000), 2020-2025
• Figure 14: Japan: Total Number of Diabetes Patients Forecast by Age Group (20-39), (40-59) & (60-79) (in 000), 2026-2034
• Figure 15: Japan: Diabetes Drug Industry Overview
• Figure 16: Japan: Diabetes Drug Market: Sales Value (in Billion USD), 2020-2025
• Figure 17: Japan: Diabetes Drug Market Forecast: Sales Value (in Billion USD), 2026-2034
• Figure 18: Japan: Diabetes Drug Market: SWOT Analysis
• Figure 19: Japan: Diabetes Drug Market: Value Chain Analysis
• Figure 20: Japan: Diabetes Drug Market: Porters Five Forces Analysis
• Figure 21: Japan: Diabetes Drug Market: Breakup of Insulin and Oral Antidiabetics (in %), 2020-2025
• Figure 22: Japan: Diabetes Drug Market Forecast: Breakup of Insulin and Oral Antidiabetics (in %), 2026-2034
• Figure 23: Japan: Oral Antidiabetics Market: Sales Value (in Million USD), 2020-2025
• Figure 24: Japan: Oral Antidiabetics Market: Sales Share of Key Classes (in %), 2020 & 2025
• Figure 25: Japan: Oral Anti-diabetics Market: Sales Share of Key Players (in %)
• Figure 26: Japan: Oral Antidiabetics Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 27: Japan: Insulin Market: Sales Value (in Million USD), 2020-2025
• Figure 28: Japan: Breakup of Insulin Market by Class (in %), 2025
• Figure 29: Japan: Insulin Market: Sales Share of Key Players (in %)
• Figure 30: Japan: Insulin Market Forecast: Sales Value (in Million USD), 2026-2034

List of Tables

• Table 1: Diagnosis of Diabetes
• Table 2: Global: Diabetes Population Breakup by Country (in 000's), 2025 and 2034
• Table 3: Japan: Total Prevalence & Number of Diabetes Patients, 2020, 2025 & 2034
• Table 4: Japan (Type1 & Type2): Total Prevalence & Number of Diabetes Patients, 2020, 2025 & 2034
• Table 5: Japan (Urban & Rural): Total Prevalence & Number of Diabetes Patients, 2020, 2025 & 2034
• Table 6: Japan (Male & Female): Total Prevalence & Number of Diabetes Patients, 2020, 2025 & 2034
• Table 7: Japan: Total Prevalence & Number of Diabetes Patients by Age Group (20-39, 40-59, 60-79 - in Millions), 2020, 2025 & 2034
• Table 8: Japan: Diabetes Drug Market: Competitive Structure